Aims-To study the patterns of p53 and Bcl-2 expression in relation to cell proliferation during human embryogenesis in order to help elucidate their potential roles in the regulation of cell proliferation and apoptosis during morphogenesis. Methods-Immunohistochemistry for p53, Bcl-2, and proliferating cell nuclear cell antigen (PCNA) proteins was performed, using a variety of monoclonal antibodies, on paraYn wax embedded sections of tissues from 68 human embryos and fetuses of between 4 and 30 weeks gestation. Results-Positive relations between sites of proliferative activity (as detected by PCNA expression) and p53 expression were found in the kidney, early developmental stages of intestine and lungs, liver, pancreas, heart, and in embryonic osteoblasts. On the other hand, positive relations between proliferative activity and Bcl-2 expression were found in the gonads, adrenal glands, in the cells of the dental lamina, hair follicles, syncytiotrophoblast, chondrocytes, and more advanced stages of intestinal development. In tissues of the central nervous system, p53 and Bcl-2 were co-expressed at the same sites but there was an inverse relation between p53/ Bcl-2 expression and proliferative activity. Conclusions-These data suggest that p53 and Bcl-2 have tissue specific and stage specific functions during embryogenesis. (J Clin Pathol: Mol Pathol 1998;51:131-137) 
The p53 gene encodes a 53 kDa nuclear phosphoprotein that is a negative regulator of the G1-S phase transition in the cell cycle. Tumour suppression by p53 is linked to a cell cycle check point induced by DNA damage, 1 in which p53 can induce either growth arrest 2 or apoptosis 3 in the damaged cells. The most important biochemical function of wild-type p53 is the sequence specific transactivation of target genes. 4 The ability of p53 to activate transcription has led to the hypothesis that genes induced by p53 might mediate its biological role as a tumour suppressor. 5 6 p53 mRNA has been demonstrated in a number of developing murine tissues 7 8 and p53 protein concentrations have been shown to decrease as normal murine development progresses. 9 p53 expression has also been demonstrated in young mice in tetraploid primary spermatocytes during the pachytene stages of meiosis. 10 Donehower and colleagues 11 showed that mice lacking a functional p53 gene develop normally but have a greater tendency to develop tumours of varying types although, more recently, p53 deficiency has been shown to be associated with a high frequency of developmental abnormalities in mice. 12 13 It has also been shown that accumulation of p53 protein occurs in early development in both irradiated and normal murine tissues.
14 Thus, there are conflicting reports on the potential importance of p53 in development. In addition, there is little information available on the expression of p53 during the development of human embryos. 15 16 Bcl-2, an integral membrane protein of the mitochondrial, nuclear, and endoplasmic reticular membranes, plays a crucial role in preventing apoptosis and in maintaining cell 4  1  1  1  1  5  3  3  3  2  6  1 1  7  8  4  7  1 4  1 1  1 2  6  8  7  7  7  6  9  4  3  4  1  1 0  4  3  3  4  1 1  6  6  6  6  1 2  4  4  4  1  1 3  3  3  3  2  14  1  -1  -1 5  1  1  1  -1 6  1  1  1  1  1 8  2  2  2  2  2 5  3  3  2  3  2 8  2  2  2  2  3 0  1  1  1  1  Total 4-8  36  19  31  19  Total 9-30  32  29  30  23  Total 4-30  68  58  61  42 survival. [17] [18] [19] The Bcl-2 mediated block of apoptosis might be the result of its influence on the release of cytochrome c from mitochondria. 18 19 Novack and Korsmeyer 20 found Bcl-2 expression in a variety of murine embryonic tissues, such as cells of the bronchial stroma, intestinal crypt epithelium, urethral buds, and metanephrogenic caps. Expression of Bcl-2 has also been demonstrated in the retinal neuroepithelium, neuroblasts of embryonic brain and spinal cord, and in digital zone cells of the limb bud blasteme, but not in cells of the interdigital zone, where rapid cell death occurs during development. From the example of diVerentiating limbs, it is clear that apoptosis as well as Bcl-2 expression are involved in the morphogenesis of a number of organs. To date, no literature has been found on Bcl-2 expression in early stages of the human embryo (up to 12 weeks of maturation). One study 21 described Bcl-2 expression in the organs of three older fetuses, but at this stage, morphological development is essentially complete.
Because both proteins are important regulators of cell growth and apoptosis, 17 21 22 a study of p53 and Bcl-2 expression in relation to proliferative rates (as measured by proliferating cell nuclear antigen (PCNA) expression), might provide data on their importance during the embryological development of various tissues and organs in humans.
Methods
Sixty eight human embryos and fetuses, all from normal pregnancies, of between 4 and 30 weeks gestation, were available as formal/saline or methacarn fixed paraYn wax embedded tissue blocks (table 1). Sections (6 µm) were prepared from each tissue block for immunohistochemistry. In embryos of advanced stages (> 15 weeks) all organs were removed and dissected before tissue fixation. Appropriate tissue preservation was confirmed by haematoxylin and eosin staining of all samples before immunohistochemistry. Any macerated or poorly preserved material was discarded.
Immunoperoxidase assays were performed on dewaxed sections using monoclonal antibodies PC-10, DO-1, DO-7, Bp53-12, and 124. Monoclonal antibodies DO-1, DO-7, and Bp53-12 23 24 are specific for human p53, monoclonal antibody 124 (Dako Ltd, Glostrup, Denmark) is specific for Bcl-2, and monoclonal antibody PC10 (Dako Ltd) is used for the detection of PCNA.
Primary antibodies were detected using a sensitive streptavidin-biotin peroxidase system (Vectastain Elite kit; Vector Laboratories, Burlingame, California, USA) as recommended by the manufacturer. 3,3'Diaminobenzidine was used as the chromogen. Primary antibody was ommitted from negative controls. Positive controls for p53, PCNA, and Bcl-2 consisted of cases of breast cancer shown previously to express these markers.
The intensity of staining was noted and the numbers of positive cells were evaluated semiquantitatively by two independent investigators and classified as either negative (no cells stained), weakly stained (< 5% of cells positive), moderately stained (between 5% and 30% of cells positive), or strongly stained (> 30% of cells positive). The ratio of marker positive embryos to total embryo count was also determined.
Results

KIDNEY
Mesonephros (primitive kidney, embryo aged 4-8 weeks)
p53 was expressed in the nuclei of secretory canal epithelium and focally in the cells of primitive renal glomeruli. PCNA was also found at the same sites. The staining intensity of both markers dropped sharply at about 7 weeks, coinciding with the involution of the mesonephros. Bcl-2 expression was weak and heterogeneous throughout the mesonephros. 1E) of earlier developmental stages. In more advanced embryos, p53 expression decreased sharply and after 12 weeks of intrauterine life was seen only in isolated hepatocytes in the periphery of liver parenchyme. Some p53 expression was found in liver blood islets. PCNA was expressed weakly in hepatocytes during earlier phases (4-6 weeks), but in later periods was only expressed focally in the periphery of liver parenchyme, in cells of blood islets, and in mesenchymal cells of diVerentiating portal canals ( fig 1F) . Bcl-2 was found only in a few mesenchymal cells of portal canals. PANCREAS p53 was demonstrated in cells of differentiating glandular epithelium, surrounding primitive mesenchyme, and the vessel wall. The intensity of expression dropped sharply during development. PCNA was found in the same localisation but the intensity of staining was much greater and did not change during the course of embryogenesis. Weak expression of Bcl-2 was seen in cells of the terminal part of the diVerentiating glandular epithelium and in the primitive mesenchyme. More intense expression was detected at earlier stages.
Thus, in liver and pancreas, p53 expression was found preferentially in sites with high proliferative activity, particularly during the earlier developmental stages. The locations for Bcl-2 expression did not correspond precisely with those of p53 but did match the expression of PCNA in more advanced fetal intestine. LUNG p53 was found in cells of primitive bronchial epithelium and surrounding mesenchyme with a dramatic decline during development, particularly after 12 weeks of intrauterine life.
Figure 1 (A) Expression of p53 (arrow) in the "neogene zone" of a human fetal kidney (11 week old fetus). (B) Expression of Bcl-2 in a human fetal kidney. Distinct expression is visible in the cells (arrow) of the metanephrogenic blasteme (12 week old fetus). (C) Expression of Bcl-2 in mesenchymal cells (arrow) of the anlage of the embryonal intestine (5 week old embryo). (D) Bcl-2 expression in the cells of diVerentiating crypts of Lieberkühn (arrow) and in the cells of primitive intramural ganglia (18 week old fetus). (E) Expression of p53 (arrow) in outer zone of fetal liver. The intensity of the expression decreases quite distinctly from the superficial to the deeper layer (9 week old fetus). (F) PCNA positive nuclei of hepatocytes in the primitive liver cords (12 week old fetus). p53 and Bcl-2 expression during the development of human embryos 133
PCNA was expressed in the same regions and also weakly in pulmonary blood vessel walls. The intensity of expression did not vary with developmental stage. Bcl-2 showed only weak expression in the mesenchymal cells surrounding the bronchial stem ( fig 3A) .
ADRENAL GLAND p53 expression was not found. PCNA was conspicuous in cells of the superficial zone of the primitive cortex ( fig 2D) . In deeper parts of the cortex, PCNA expression was less evident. From 10 weeks of intrauterine life, it was also present in foci of the medullary cells and primitive sinusoids. Bcl-2 expression was seen only in foci of medullary cells ( fig 3B) .
GONADS
p53 was expressed very weakly in coelomic and mesenchymal cells of the primitive gonad and expression disappeared upon maturation. PCNA was expressed very strongly in the gonocytes and coelomic cells of medullary bands found in early stages (4-8 weeks) but decreased during development. Bcl-2 colocalised with PCNA.
HEART
The p53 protein was demonstrated in primitive myoblasts of both compact and spongy layers but concentrations diminished as development progressed. It was also found sporadically in epicardial and endocardial cells. PCNA was noted in the same localisation but with an intensity gradient decreasing from the spongy to compact layer. Bcl-2 expression was not seen.
PRIMITIVE ORGANS OF THE CENTRAL NERVOUS
SYSTEM (CNS) p53 was found during the earlier stages of development (4-8 weeks) in the cells of the lamina epithelialis, weakly in the mesenchyme of the choroid plexus, in isolated cells of the cerebral cortex, in cells of the bulbus olfactorius, in the spinal ganglia ( figure 3C ), in the mantle layer of the spinal cord, and in ectodermal cells of otocysts. In more advanced fetuses (9-30 weeks), p53 expression disappeared dramatically, with the exception of only one case in which expression was weak. PCNA expression was found in the cells of the germinal zone of the CNS anlage organ during embryogenesis and was also marked in fetal nervous tissues, mostly in the primitive cerebellar cortex, parahippocampal gyrus, thalamus, choroid plexus, cerebral cortex, and brain stem. Bcl-2 was expressed in the neuroblasts of the germinal and mantle zones of the spinal cord (fig 3D) , of the brain ( fig 3E) and spinal ganglia, the cells of the choroid plexus, otocysts, and primitive retina. These showed a tendency towards a stage dependent decrease. Thus, in the CNS, an inverse relation was seen between sites of
Figure 2 (A) Expression of PCNA in the "neogene zone" of human fetal kidney (10 week old fetus). (B) Expression of PCNA in the mesenchymal and epithelial cells of the fetal intestine (13 week old fetus). (C) p53 expression of scattered cells (arrow) of embryonal intestine (7 week old embryo). (D) Expression of PCNA in the superficial zone of the primitive cortex of the fetal adrenal gland (11 week old fetus). Thus, in the mesonephros, the topography of p53 expression corresponded closely with PCNA expression but not with Bcl-2 expression and the expression of both proteins decreased during development. In the metanephros, the expression of all three markers appeared in the same topographical regions without distinct changes during development.
p53 and PCNA expression. During earlier stages of development, p53 and Bcl-2 were often co-expressed.
OTHER TISSUES AND ORGANS p53 expression was found in the trabecular osteoblasts of the cranial skeleton in fetal developmental stages. PCNA expression corresponded closely with p53 and/or Bcl-2. Bcl-2 was expressed in cells of epithelial buds in the dental crest (fig 3F) , ectodermal cells of the anlage of hair follicles, syncytiotrophoblast, and chondrocytes of the digital zone of limb anlages.
Discussion
We have shown that genes involved in the regulation of the cell cycle of human adults are active from the earliest phases of embryogenesis. The reason for the massive accumulation of the p53 product in embryonic cells, detectable using immunohistochemical methods, is not clear but might testify to its important role in morphogenesis. The finding of greater amounts of the p53 protein in early embryos (before the end of organogenesis) supports the idea that p53 controls the elimination of cells with genetic abnormalities
Figure 3 (A) Expression of Bcl-2 (arrow) in the mesenchymal cells surrounding the bronchial stem (11 week old fetus). (B) Expression of Bcl-2 in the cells (arrow) of the medular anlage diVerentiating adrenal gland (11 week old fetus). (C) Expression of p53 in some cells (arrow) of a spinal ganglion anlage (6 week old embryo). (D) Expression of Bcl-2 in the cells of the germinal (G) and mantel (M) zone of an embryonal spinal cord (7 week old embryo). (E) Expression of Bcl-2 in the neuroblasts of brain cortex (B) and the cells of choroid plexus (CH) (8 week old embryo). (F) Bcl-2 expression of the cells of the epithelial bud (arrow) of the dental crest (6 week old embryo). p53 and Bcl-2 expression during the development of human embryos 135
during the early stage of embryogenesis, possibly by inducing p53 mediated apoptosis. 25 We found immunohistochemical staining of p53 in only a proportion of embryos examined. This might reflect the earlier finding that p53 is not absolutely necessary for development or regulation of the cell cycle in all embryos, 11 and also that some familial diVerences in the ability to utilise or synthesise p53 could be involved. It is also possible that variability of tissue processing might have prevented the detection of low concentrations of p53 in some cases, and a more sensitive technique might prove successful here. 14 It is well known that wild-type p53 has a very short half life. However, it may be stabilised during DNA repair 14 induced by a variety of mutagenic agents, including gamma and UV irradiation. 26 27 Although it is not likely that extensive DNA damage could explain p53 accumulation in our samples, we cannot fully exclude the possibility that p53 might be induced by DNA damage or upregulated in response to fetal trauma. 16 There are other known mechanisms responsible for stabilisation of p53, which are also associated with its inactivation. According to recent data, p53 inactivation is usually the result of deletion and mutation, and only occasionally caused by independent bi-allelic point mutations. 28 Inactivation might be the result of alterations in other genes that influence p53 activity, such as mdm-2 oncogene overexpression and products of viral E6 and ElB genes. 28 29 However, these mechanisms are not likely to be operative during embryonic life. Macleod and colleagues 30 have studied the p53 dependent cell death pathway in the developing mouse nervous system and have demonstrated the importance of the retinoblastoma (Rb) gene on p53 protein induction. We can also speculate about synthesis of more stable embryonic isotypes of p53. Our results suggest that p53 expression in specific organs and tissues and at specific stages of development is probably important. The importance of p53 control in the development of specific tissues is underlined by recent studies showing that p53 overexpression causes defects in kidney development. 31 In addition, Bcl-2 mediated regulatory pathways might be involved in protection from cell death at specific times during the development of some organs. Our results show that p53 and Bcl-2 were expressed simultaneously in human embryonic tissues only in the central nervous system, suggesting that both proteins are important regulators of CNS development. This is supported by recent data showing that CNS abnormalities are common in p53 null mice 12 13 and that neuronal diVerentiation is aVected by p53 concentrations. 32 In some developing tissues, p53 expression correlated positively with sites of high proliferative activity. In these tissues, higher p53 expression might be a reflection of regulatory pathways operating to subdue "inadequate" proliferation, or it may be necessary for the control of the higher rate of genomic mistakes that might arise more frequently at sites of intense cell division. It would be interesting to elucidate whether the rate of apoptosis is altered in these tissues. In a few components of the CNS there was an inverse relation between proliferation and p53 expression. Thus, in some development stages of the CNS, p53 might play a less important role and its regulatory eVects might be substituted by other regulatory genes, including the Bcl-2 gene, which protects irreplaceable neural cells against death.
The high expression of both p53 and Bcl-2 in the presence of low level cell proliferation seen in some embryonic and fetal tissues might reflect attempts to ensure survival of the cells during critical periods of development. The evaluation of the localisation and quantity of Bcl-2 expression also demonstrated that only in some organs and cell types (more advanced intestine, gonads, dental crest, hair follicles, syncytiotrophoblast, and chondrocytes) did the number of Bcl-2 positive cells correlate positively with proliferative activity. We assume, therefore, that in these tissues Bcl-2 might ensure cell survival or participate in the control of cell division.
Our results support the hypothesis that embryogenesis is under multiple levels of control.
14 This control could be mediated for each organ and developmental stage by diVerent regulatory pathways that trigger time dependent promotion of proliferation, diVerentiation, and/or apoptosis. These findings might also have implications for the study of tissue susceptibility to teratogenic and carcinogenic insults. 
